logo
Casey's Announces Fourth Quarter and Fiscal Year Results

Casey's Announces Fourth Quarter and Fiscal Year Results

Business Wire2 days ago

ANKENY, Iowa--(BUSINESS WIRE)--Casey's General Stores, Inc., ("Casey's" or the "Company") (Nasdaq symbol CASY) one of the leading convenience store chains in the United States, today announced financial results for the three months and year ended April 30, 2025.
Fourth Quarter 2025 Key Highlights 1
Diluted EPS of $2.63, up 12.4% from the same period a year ago. Net income was $98.3 million, up 13.0%, and EBITDA 2 was $263.0 million, up 20.1%, from the same period a year ago.
Inside same-store sales up 1.7% compared to the prior year, and 7.4% on a two-year stack basis, with an inside margin of 41.2%. Total inside gross profit increased 12.5% to $582.4 million compared to the prior year.
Fuel same-store gallons were up 0.1% compared to the prior year with a fuel margin of 37.6 cents per gallon. Total fuel gross profit increased 21.4% to $307.8 million compared to the prior year.
In June, Casey's increased the quarterly dividend 14% to $0.57 per share, marking the 26th consecutive annual increase.
Fiscal Year 2025 Key Highlights
Diluted EPS of $14.64 up 9.0% over the prior year. Net income was $546.5 million, up 8.9%, and EBITDA was $1.2 billion, up 13.3%, from the prior year.
The Company built or acquired 270 stores in the fiscal year, the most in the Company's history. This included the Fikes Wholesale acquisition and its 198 CEFCO convenience stores.
Casey's Rewards grew to over 9 million members by year-end.
The balance sheet remains strong, finishing the year with a debt-to-EBITDA ratio 3 of 1.9x.
'Casey's delivered another record fiscal year as our team continued to execute on our three-year strategic plan, reaching $546.5 million of net income and $1.2 billion in EBITDA," said Darren Rebelez, President and CEO. 'Inside same-store sales outperformed the industry, up 2.6%, or 7.1% on a two-year stack basis, led by strong performance in hot sandwiches and bakery as well as alcoholic and non-alcoholic beverages. Our fuel team grew market share and produced a healthy margin, as fuel gross profit increased 10.7% from the prior year. The operations team performed exceptionally well during the year, driving strong performance, integrating the most new units in Casey's history, while reducing same-store labor hours for the twelfth consecutive quarter.'
Fourth quarter net income, diluted EPS, and EBITDA were up versus the same period the prior year primarily due to higher inside and fuel gross profit partially offset by higher operating expense due to operating 246 additional stores.
1 During the prior year's fourth quarter Casey's had one additional operating day due to the leap year. This unfavorably impacted same-store and total results for the quarter by approximately 100 basis points; the full year impact was approximately 25 basis points.
2 EBITDA is reconciled to net income below.
3 As calculated under the covenants in the Company's credit facilities
Expand
Inside
Three Months Ended April 30,
Twelve Months Ended April 30,
2025
2024
2025
2024
Inside sales (in thousands)
$
1,413,593
$
1,257,375
$
5,755,649
$
5,188,994
Inside same-store sales
1.7
%
5.6
%
2.6
%
4.4
%
Grocery and general merchandise same-store sales
1.8
%
4.3
%
2.3
%
3.5
%
Prepared food and dispensed beverage same-store sales
1.5
%
8.8
%
3.5
%
6.8
%
Inside gross profit (in thousands)
$
582,396
$
517,613
$
2,389,448
$
2,128,822
Inside margin
41.2
%
41.2
%
41.5
%
41.0
%
Grocery and general merchandise margin
34.8
%
34.4
%
35.0
%
34.1
%
Prepared food and dispensed beverage margin
57.8
%
58.1
%
58.2
%
58.7
%
Expand
For the quarter, total inside sales were up 12.4% for the quarter and total inside gross profit was up 12.5%. Inside same-store sales were up 1.7%, or 7.4% on a two-year stack basis, driven by strong performance in bakery and hot and cold food in the prepared food and dispensed beverage category as well as non-alcoholic beverages in the grocery and general merchandise category. Inside margin was flat compared to the same period in the prior year.
For the quarter, total fuel gallons sold increased 17.8% compared to the prior year primarily due to operating more stores, while same-store gallons sold were up 0.1% versus the prior year. Fuel gross profit was up 21.4% versus the prior year. The Company sold $4.3 million in renewable fuel credits (RINs) in the fourth quarter, while the company sold $1.0 million RINs in the same period last year.
Total operating expenses increased 14.5% for the fourth quarter. Operating 246 more stores than the prior year accounted for approximately 12% of the increase, including one-time deal and integration costs of approximately $4 million from the Fikes acquisition. Insurance expense contributed approximately 3% of the increase. Same-store employee expense was approximately flat, as the increases in wage rates were substantially offset by a reduction in same-store labor hours.
4 Fuel category does not include wholesale fuel nor terminal activity, which is included in Other.
Expand
Expansion
Store Count
April 30, 2024
2,658
New store construction
35
Acquisitions
235
Acquisitions not opened
(1
)
Prior acquisitions opened
1
Closed
(24
)
April 30, 2025
2,904
Expand
Liquidity
At April 30, 2025, the Company had approximately $1.2 billion in available liquidity, consisting of approximately $327 million in cash and cash equivalents on hand and approximately $900 million in undrawn borrowing capacity on existing lines of credit.
Share Repurchase
During the fourth quarter, the Company did not repurchase any shares. The Company has approximately $295 million remaining under its existing share repurchase authorization.
Dividend
At its June meeting, the Board of Directors voted to increase the quarterly dividend by 14% to $0.57 per share, which is the 26th consecutive year increasing the dividend. The dividend is payable August 15, 2025, to shareholders of record on August 1, 2025.
Fiscal 2026 Outlook
Casey's expects the following performance during fiscal 2026. The Company expects EBITDA to increase 10% to 12%. The Company expects inside same-store sales to increase 2% to 5% and inside margin of approximately 41%. The Company expects same-store fuel gallons sold to be negative 1% to positive 1%. Total operating expenses are expected to increase approximately 8% to 10%. The Company expects to open at least 80 stores in fiscal 2026, through a mix of M&A and new store construction, bringing the three-year strategic plan period total to approximately 500 stores. Net interest expense is expected to be approximately $110 million. Depreciation and amortization is expected to be approximately $450 million and the purchase of property and equipment is expected to be approximately $600 million. The tax rate is expected to be approximately 24% to 26% for the year.
Casey's General Stores, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(Dollars in thousands)
(Unaudited)
Twelve months ended April 30,
2025
2024
Cash flows from operating activities:
Net income
$
546,520
$
501,972
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
403,647
349,797
Amortization of debt related costs
2,312
1,111
Change in excess replacement cost over LIFO inventory valuation
11,530
12,499
Share-based compensation
47,732
41,379
Loss on disposal of assets and impairment charges
12,401
6,414
Deferred income taxes
59,958
53,252
Changes in assets and liabilities:
Receivables
(1,297
)
(31,246
)
Inventories
(7,756
)
(51,785
)
Prepaid expenses
3,658
(3,684
)
Accounts payable
(20,782
)
(8,731
)
Accrued expenses
21,525
14,387
Income taxes
15,460
5,112
Other, net
(4,054
)
2,476
Net cash provided by operating activities
1,090,854
892,953
Cash flows from investing activities:
Purchase of property and equipment
(506,224
)
(522,004
)
Payments for acquisitions of businesses, net of cash acquired
(1,239,249
)
(330,032
)
Proceeds from sales of property and equipment
18,805
26,680
Net cash used in investing activities
(1,726,668
)
(825,356
)
Cash flows from financing activities:
Proceeds from long-term debt
1,100,000

Repayments of long-term debt
(239,492
)
(53,656
)
Payments of debt related costs
(5,891
)

Payments of cash dividends
(72,309
)
(62,918
)
Repurchase of common stock and payment of related excise taxes
(734
)
(104,898
)
Tax withholdings on employee share-based awards
(25,580
)
(18,512
)
Net cash provided by (used in) financing activities
755,994
(239,984
)
Net increase (decrease) in cash and cash equivalents
120,180
(172,387
)
Cash and cash equivalents at beginning of the period
206,482
378,869
Cash and cash equivalents at end of the period
$
326,662
$
206,482
Expand
RECONCILIATION OF NET INCOME TO EBITDA
We define EBITDA as net income before net interest expense, income taxes, depreciation and amortization. EBITDA is not considered to be a GAAP measure, and should not be considered as a substitute for net income, cash flows from operating activities or other income or cash flow statement data. This measure has limitations as an analytical tool, and should not be considered in isolation or as substitutes for analysis of our results as reported under GAAP. We strongly encourage investors to review our financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.
We believe EBITDA is useful to investors in evaluating our operating performance because securities analysts and other interested parties use such calculations as a measure of financial performance and debt service capabilities, and it is regularly used by the Company for internal purposes including our capital budgeting process, evaluating acquisition targets, assessing performance, and awarding incentive compensation.
Because non-GAAP financial measures are not standardized, EBITDA, as defined by us, may not be comparable to similarly titled measures reported by other companies. It therefore may not be possible to compare our use of this non-GAAP financial measure with those used by other companies.
The following table contains a reconciliation of net income to EBITDA for the three and twelve months ended April 30, 2025 and 2024:
NOTES:
Gross Profit is defined as revenue less cost of goods sold (exclusive of depreciation and amortization)
Inside is defined as the combination of Grocery and General Merchandise and Prepared Food and Dispensed Beverage
This release contains statements that may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those related to expectations for future periods, possible or assumed future results of operations, financial conditions, liquidity and related sources or needs, business and/or integration strategies, plans and synergies, supply chain, growth opportunities, performance at our stores. There are a number of known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from any results expressed or implied by these forward-looking statements, including but not limited to the execution of our strategic plan, the integration and financial performance of acquired stores, wholesale fuel, inventory and ingredient costs, distribution challenges and disruptions, the impact and duration of the conflict in Ukraine or other geopolitical disruptions, as well as other risks, uncertainties and factors which are described in the Company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as filed with the Securities and Exchange Commission and available on our website. Any forward-looking statements contained in this release represent our current views as of the date of this release with respect to future events, and Casey's disclaims any intention or obligation to update or revise any forward-looking statements in the release whether as a result of new information, future events, or otherwise.
Corporate information is available at this website: https://www.caseys.com. Earnings will be reported during a conference call on June 10, 2025. The call will be broadcast live over the Internet at 7:30 a.m. CDT. To access the call, go to the Events and Presentations section of our website at https://investor.caseys.com/events-presentations. No access code is required. A webcast replay of the call will remain available in an archived format on the Events and Presentations section of our website at https://investor.caseys.com/events-presentations for one year after the call.
CASY-IR

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Palantir Just Popped 40%, But Is Snowflake Still the Quiet Killer in AI?
Palantir Just Popped 40%, But Is Snowflake Still the Quiet Killer in AI?

Business Insider

time41 minutes ago

  • Business Insider

Palantir Just Popped 40%, But Is Snowflake Still the Quiet Killer in AI?

Palantir (PLTR) ripped higher in May, up 40.3% in a month when the Nasdaq basically slept. The spark? A fresh partnership with Databricks (yes, the same Databricks Nvidia just backed), plus a string of government wins across immigration, defense, and even the IRS. That's vintage Palantir: big, bold, and all-in on public sector scale. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter And the market loved it. This is Palantir at its most potent—throwing elbows in the AI analytics ring and still landing contracts with agencies that don't mess around. The company's vision of 'AI with consequences' is resonating. That's translating into real revenue and serious stock action. Snowflake Stays Cool, But Don't Mistake It For Passive While Palantir was printing headlines, Snowflake (SNOW) barely budged. But that doesn't mean nothing's happening. Snowflake is the definition of stealth strength. It's the clean, enterprise-friendly data infrastructure play—plugged deep into AWS, Azure, and Google Cloud. And here's the twist: analysts say Snowflake's commercial reach may actually outpace Palantir's total addressable market over the long haul. Snowflake lives in the subscription SaaS world. Palantir lives on custom, high-touch deployments. That's the clash: scalability vs. depth. Two AI Strategies. One Collision Course. Palantir is going hyper-targeted: government, defense, complex systems, all infused with AI. Snowflake is building universal tools for every corporate data team on Earth. Different lanes, same race. If the AI wave stays high and wide, Snowflake's architecture might have more runway. But if regulation and geopolitical tension put data and defense front and center? That's Palantir's jungle. The Verdict Comes Down to Lightning vs. Ice Palantir's got momentum, headlines, and that sweet Databricks nod. But Snowflake's commercial footprint is enormous—and quietly expanding. One's loud, the other's lethal. Investors need to ask: do you want the stock that can 2x on a single AI headline? Or the one that could 10x silently over five years because it's baked into every Fortune 500 data stack? Right now, the market's hyped on Palantir. But the AI war is just warming up. And Snowflake isn't showing its hand yet. What Do Analysts Think Is the Better Buy: Palantir or Snowflake? Palantir is going hyper-targeted: government, defense, complex systems, all infused with AI. Snowflake is building universal tools for every corporate data team on Earth. Different lanes, same race. Investors can compare Palantir and Snowflake using the TipRanks Stock Comparison Tool. Snowflake (SNOW) currently trades at $208.24. Analysts project a robust upside for the data cloud giant. Its average price target hits $226.74, signaling an 8.88% potential climb. The consensus stands firm at a 'Strong Buy'. Snowflake also boasts a Smart Score of 5. Its market capitalization reaches $69.48 billion, with a P/E ratio of -50.12. Palantir (PLTR) charts a different course. Trading at $132.81, analysts foresee a downturn for the AI analytics firm. Its average price target hovers at $101.06, indicating a 23.91% potential downside. The consensus leans towards a 'Hold' rating. Palantir holds a Smart Score of 4. The company commands a significantly larger market capitalization at $313.42 billion, with a P/E ratio of 576.68. This direct comparison highlights Wall Street's current preferences. Snowflake draws strong buy signals and projected upside. Palantir, despite recent surges, faces a 'Hold' consensus and forecasted decline. The market clearly evaluates these AI titans on distinct metrics.

Critical One Makes Strategic Uranium Asset Divestment
Critical One Makes Strategic Uranium Asset Divestment

Yahoo

timean hour ago

  • Yahoo

Critical One Makes Strategic Uranium Asset Divestment

TORONTO, June 12, 2025 (GLOBE NEWSWIRE) -- Critical One Energy Inc. (formerly Madison Metals Inc.) ('Critical One' or the 'Company') (CSE: CRTL) (OTCQB: MMTLF) (FSE: 4EF0) is pleased to announce that Dark Star Minerals Inc. ('Dark Star') (CSE: BATT) (FSE: P0W), a well-managed, uranium-focused, publicly-listed company, has entered into an acquisition agreement with Critical One to acquire 100% of its interests in the Khan and Cobra Uranium Projects, located in Namibia's highly prospective Erongo uranium province. 'Divesting the Company's uranium assets and focusing on the Howells Lake Antimony-Gold Project ('Howells Lake Project') enhances our shareholder value by strategically refining the Company's critical metals and minerals mission,' said Duane Parnham, Executive Chairman and CEO of Critical One. 'I believe this shift in our critical metals strategy aligns with global market trends driven by the energy transition, and will offer higher growth potential and improved returns. Howell Lake's antimony deposits allow us to capitalize on the rapidly growing demand for these critical metals. Plus, the project provides gold exploration upside in a period when the yellow metal's value is reaching all-time market highs.' Parnham added, 'By forming this alliance with Dark Star, our investment in uranium continues to have great potential. This divestiture allows Critical One to focus on its capital allocation on high-margin, high-demand critical minerals, thereby optimizing our portfolio for long-term profitability, reducing exposure to market risks, and strengthening our competitive position in a future-focused industry, ultimately driving sustainable value creation for shareholders.' Under the terms of the letters of intent agreement ('LOI'), Dark Star has the opportunity to acquire all of Critical One's interest in the Khan and Cobra Uranium Projects through staged cash payments and issuances of common shares to the Company over a two-year period. No fairness opinion or independent valuation of the uranium assets was sought by Critical One or Dark Star for this agreement. A summary of terms for the LOI is provided below, concurrently issued in the Dark Star news release dated June 12, 2025. Payment Date Cash Payment Amount Securities Issuance On the date of execution of this LOI (the 'LOI Execution Date') US$10,000 - Upon the later of: (a) the date that is five days of the LOI Execution Date; and (b) receipt of Exchange approval for the LOI - 200,000 common shares (each, a 'Share') of Dark Star Upon the execution of the Definitive Agreement (the 'Definitive Agreement Execution Date') US$150,000 14,000,000 Dark Star Shares On or before the date that is four (4) months from the Definitive Agreement Execution Date US$100,000 - On or before first anniversary of the Definitive Agreement Execution Date US$250,000 US$1,000,000 in Dark Star Shares On or before second anniversary of the Definitive Agreement Execution Date US$250,000 US$750,000 in Dark Star Shares Total: US$760,000 Once the staged cash and share issuances reach a combined value above US$3.5 million (as outlined in the table), Critical One will be granted a 2% gross overriding royalty on all metals produced from the two uranium projects. Upon signing of the LOI, Critical One received US$10,000 in cash and was issued 200,000 common shares of Dark Star, priced at CDN$0.075 at close of business on June 11, 2025. This will be followed by subsequent cash and common share payments in accordance with a definitive agreement to be signed within 60 days. The definitive agreement will be subject to the approval of the usual regulatory approvals. About Critical One Energy Inc. Critical One Energy Inc. (formerly Madison Metals Inc.) is a forward-focused critical minerals and upstream energy company, powering the future of clean energy and advanced technologies. The addition of the Howells Lake Antimony-Gold Project broadens the Company's exposure to antimony, one of the most in-demand critical minerals. Backed by seasoned management expertise and prime resource assets, Critical One is strategically positioned to meet the rising global demand for critical minerals and metals. Its mine exploration portfolio is led by antimony-gold exploration potential in Canada and uranium investment interests in Namibia, Africa. By leveraging its technical, managerial, and financial expertise, the Company upgrades and creates high-value projects, thereby driving growth and delivering value to its shareholders. Additional information about Critical One Energy Inc. can be found at and on the Company's SEDAR+ profile at For further information, please contact: Duane ParnhamExecutive Chairman & CEOCritical One Energy Inc. +1 (416) 489-0092ir@ Media inquiries: Adam BelloManager, Media & Analyst RelationsPrimoris Group Inc.+1 (416) 489-0092media@ Neither the Canadian Securities Exchange nor CIRO accepts responsibility for the adequacy or accuracy of this release. Forward-looking Statements This news release contains 'forward-looking information' within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as 'may', 'will', 'expect', 'likely', 'should', 'would', 'plan', 'anticipate', 'intend', 'potential', 'proposed', 'estimate', 'believe' or the negative of these terms, or other similar words, expressions, and grammatical variations thereof, or statements that certain events or conditions 'may' or 'will' happen, or by discussions of strategy. Forward-looking information contained in this press release includes, but is not limited to, statements relating to the terms and timing of the private placement described in this press release and the anticipated uses of the proceeds raised from such private placement. Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that: the Company will receive all necessary approval required in order to complete the issuance of the securities pursuant to the private placement described in in this press release; and that there will be sufficient interest from potential investors in order to complete the private placement on the terms as described herein or at all. However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, the risk that the Company will not be able to proceed with the issuance of units on the terms described in this press release or at all. Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. The Company does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking in to access your portfolio

Kelun-Biotech's Novel CLDN18.2 ADC SKB315 IND in Combination with Tagolizumab Receives NMPA Approval for the First-Line Treatment of Gastric/Gastro-oesophageal Junction Cancer
Kelun-Biotech's Novel CLDN18.2 ADC SKB315 IND in Combination with Tagolizumab Receives NMPA Approval for the First-Line Treatment of Gastric/Gastro-oesophageal Junction Cancer

Yahoo

timean hour ago

  • Yahoo

Kelun-Biotech's Novel CLDN18.2 ADC SKB315 IND in Combination with Tagolizumab Receives NMPA Approval for the First-Line Treatment of Gastric/Gastro-oesophageal Junction Cancer

CHENGDU, China, June 12, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that the Company has received a clinical trial notice approving the investigational new drug application for the its CLDN18.2-directed antibody-drug conjugate (ADC) SKB315 in combination of the anti-programmed death ligand 1 (PD-L1) monoclonal antibody (mAb) tagitanlimab for the first-line treatment of gastric cancer / gastro-oesophageal junction cancer (GC/GEJC) from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). SKB315 is a novel CLDN18.2-directed ADC for advanced solid tumors, configured with a proprietary, in-house developed humanized CLDN18.2 mAb and a differentiated payload-linker design. Building upon ongoing monotherapy studies in CLDN-expressing tumors such as GC/GEJC and pancreatic ductal adenocarcinoma, the Company is also initiating clinical studies of its combination therapy with immunotherapy for the first-line treatment of CLDN-positive GC/GEJC. Tagitanlimab is the first PD-L1 mAb to receive authorization for the first-line treatment of nasopharyngeal carcinoma (NPC). It has been approved by the NMPA for marketing in China as a combination therapy with cisplatin and gemcitabine for the first-line treatment of patients with recurrent or metastatic (R/M) NPC, as well as monotherapy for the treatment of patients with R/M NPC who have failed after prior 2L+ chemotherapy. Previously, tagitanlimab in combination with TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) granted Breakthrough Therapy Designation by the CDE of the NMPA of China for the first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without actionable genomic alterations. Encouraging clinical development progress has been made in recent years with combination strategies based on PD-(L)1 antibodies. The innovative ADC SKB315 combined with the PD-L1 monoclonal antibody tagitanlimab is expected to generate synergistic effects through their distinct mechanisms of action, overcoming tumor heterogeneity among different patients and delivering greater survival benefits. About Kelun-BiotechKelun-Biotech ( is a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@ View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store